NCR1 and neoplasm: As shown in Figure 2C, the binding of human NKp46-Ig to BJAB, MCF-7, and C1R tumor cells was not affected by the presence or absence of either 09 or 9E2 mAb antibodies, indicating that the NKp46 tumor binding site is distinct from these mAb binding sites.